These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35519188)

  • 41. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.
    Hosseini M; Chen W; Xiao D; Wang C
    Precis Clin Med; 2021 Mar; 4(1):1-16. PubMed ID: 33842834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models.
    Fadlalla M; Ahmed M; Ali M; Elshiekh AA; Yousef BA
    Curr Pharmacol Rep; 2022; 8(3):212-226. PubMed ID: 35381996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).
    De Vita S; Chini MG; Lauro G; Bifulco G
    RSC Adv; 2020 Nov; 10(67):40867-40875. PubMed ID: 35519188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.
    Oktay L; Erdemoğlu E; Tolu İ; Yumak Y; Özcan A; Acar E; Büyükkiliç Ş; Olkan A; Durdaği S
    Turk J Biol; 2021; 45(4):459-468. PubMed ID: 34803447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.
    DurdaĞi S
    Turk J Biol; 2020; 44(3):185-191. PubMed ID: 32595355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of SARS-CoV-2 main protease by phenolic compounds from
    Abd El-Mordy FM; El-Hamouly MM; Ibrahim MT; El-Rheem GA; Aly OM; Abd El-Kader AM; Youssif KA; Abdelmohsen UR
    RSC Adv; 2020 Aug; 10(53):32148-32155. PubMed ID: 35518160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-HIV drug repurposing against SARS-CoV-2.
    Sang P; Tian SH; Meng ZH; Yang LQ
    RSC Adv; 2020 Apr; 10(27):15775-15783. PubMed ID: 35493667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction.
    Taguchi YH; Turki T
    PLoS One; 2020; 15(9):e0238907. PubMed ID: 32915876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultrasound assisted synthesis of 3-alkynyl substituted 2-chloroquinoxaline derivatives: Their
    Shahinshavali S; Hossain KA; Kumar AVDN; Reddy AG; Kolli D; Nakhi A; Rao MVB; Pal M
    Tetrahedron Lett; 2020 Oct; 61(40):152336. PubMed ID: 32868957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.
    Yadav M; Dhagat S; Eswari JS
    Eur J Pharm Sci; 2020 Dec; 155():105522. PubMed ID: 32827661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis.
    Kumar N; Awasthi A; Kumari A; Sood D; Jain P; Singh T; Sharma N; Grover A; Chandra R
    J Biomol Struct Dyn; 2022 Jan; 40(1):101-116. PubMed ID: 32815796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An
    Alexpandi R; De Mesquita JF; Pandian SK; Ravi AV
    Front Microbiol; 2020; 11():1796. PubMed ID: 32793181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an
    Ferraz WR; Gomes RA; S Novaes AL; Goulart Trossini GH
    Future Med Chem; 2020 Oct; 12(20):1815-1828. PubMed ID: 32787684
    [No Abstract]   [Full Text] [Related]  

  • 57. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
    Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
    Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.